Cargando…

Computational target-based drug repurposing of elbasvir, an antiviral drug predicted to bind multiple SARS-CoV-2 proteins

Coronavirus disease 19 (COVID-19) is a severe acute respiratory syndrome caused by SARS-CoV-2 (2019-nCoV). While no drugs have yet been approved to treat this disease, small molecules effective against other viral infections are under clinical evaluation for therapeutic abatement of SARS-CoV-2 infec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Balasubramaniam, Meenakshisundaram, Reis, Robert J. Shmookler
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	ChemRxiv 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7263767/ https://www.ncbi.nlm.nih.gov/pubmed/32511290 http://dx.doi.org/10.26434/chemrxiv.12084822

Ejemplares similares

Combined in silico and in vitro approaches identified the antipsychotic drug lurasidone and the antiviral drug elbasvir as SARS-CoV2 and HCoV-OC43 inhibitors
por: Milani, Mario, et al.
Publicado: (2021)

New Approaches and Repurposed Antiviral Drugs for the Treatment of the SARS-CoV-2 Infection
por: Bauso, Luana Vittoria, et al.
Publicado: (2021)

Discovery of adapalene and dihydrotachysterol as antiviral agents for the Omicron variant of SARS-CoV-2 through computational drug repurposing
por: Fidan, Ozkan, et al.
Publicado: (2022)

Repurposing of potential antiviral drugs against RNA-dependent RNA polymerase of SARS-CoV-2 by computational approach
por: Gangadharan, Sivakumar, et al.
Publicado: (2022)

Glial Fibrillary Acidic Protein: A Biomarker and Drug Target for Alzheimer’s Disease
por: Ganne, Akshatha, et al.
Publicado: (2022)

Computational drug repurposing against SARS-CoV-2 reveals plasma membrane cholesterol depletion as key factor of antiviral drug activity
por: Barsi, Szilvia, et al.
Publicado: (2022)

Computational guided approach for drug repurposing against SARS-CoV-2
por: Anand, Jigisha, et al.
Publicado: (2021)

Drug repurposing against SARS-CoV-2 using computational approaches
por: Kumar, Sumit, et al.
Publicado: (2022)

In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2
por: Pizzorno, Andrés, et al.
Publicado: (2020)

Computational approaches for drug repositioning and repurposing to combat SARS-CoV-2 infection
por: Panda, Subhamay, et al.
Publicado: (2022)

Clinical Trials of Repurposed Antivirals for SARS-CoV-2
por: Martinez, Miguel Angel
Publicado: (2020)

Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV
por: Aherfi, Sarah, et al.
Publicado: (2021)

Drug-induced phospholipidosis confounds drug repurposing for SARS-CoV-2
por: Tummino, Tia A., et al.
Publicado: (2021)

Rapamycin: Drug Repurposing in SARS-CoV-2 Infection
por: Patocka, Jiri, et al.
Publicado: (2021)

Thermodynamic and structural insights into the repurposing of drugs that bind to SARS-CoV-2 main protease
por: Wan, Shunzhou, et al.
Publicado: (2021)

Structural insights into pro-aggregation effects of C. elegans CRAM-1 and its human ortholog SERF2
por: Balasubramaniam, Meenakshisundaram, et al.
Publicado: (2018)

Targeting SARS-CoV-2 Main Protease: A Computational Drug Repurposing Study
por: Baby, Krishnaprasad, et al.
Publicado: (2021)

Computational repurposing of asthma drugs as potential inhibitors of SARS-CoV-2 M(pro)
por: Hussain, A., et al.
Publicado: (2022)

Exploring the SARS-CoV-2 virus-host-drug interactome for drug repurposing
por: Sadegh, Sepideh, et al.
Publicado: (2020)

L1000 connectivity map interrogation identifies candidate drugs for repurposing as SARS-CoV-2 antiviral therapies
por: Sendama, Wezi
Publicado: (2020)

A drug repurposing screen identifies hepatitis C antivirals as inhibitors of the SARS-CoV2 main protease
por: Baker, Jeremy D., et al.
Publicado: (2021)

In silico molecular docking analysis for repurposing approved antiviral drugs against SARS-CoV-2 main protease
por: Khater, Ibrahim, et al.
Publicado: (2021)

Tackling SARS-CoV-2: proposed targets and repurposed drugs
por: Joshi, Siddhi, et al.
Publicado: (2020)

Anti-HIV drug repurposing against SARS-CoV-2
por: Sang, Peng, et al.
Publicado: (2020)

Applying polypharmacology approach for drug repurposing for SARS-CoV2
por: Jamir, Esther, et al.
Publicado: (2022)

Drug repurposing for SARS-CoV-2 (COVID-19) treatment
por: Mtewa, Andrew G., et al.
Publicado: (2022)

Improved and optimized drug repurposing for the SARS-CoV-2 pandemic
por: Cohen, Sarel, et al.
Publicado: (2023)

SARS-CoV-2: An Update on Potential Antivirals in Light of SARS-CoV Antiviral Drug Discoveries
por: Elshabrawy, Hatem A.
Publicado: (2020)

Antiviral drugs against SARS-CoV-2
por: Aiello, Tommaso Francesco, et al.
Publicado: (2022)

Computational guided drug repurposing for targeting 2′-O-ribose methyltransferase of SARS-CoV-2
por: Sharma, Kedar, et al.
Publicado: (2020)

Telaprevir is a potential drug for repurposing against SARS-CoV-2: computational and in vitro studies
por: Mahmoud, Amal, et al.
Publicado: (2021)

Proteins in aggregates functionally impact multiple neurodegenerative disease models by forming proteasome-blocking complexes
por: Ayyadevara, Srinivas, et al.
Publicado: (2015)

Drug Repurposing for the Identification of Compounds with Anti-SARS-CoV-2 Capability via Multiple Targets
por: Yu, Pei-Chen, et al.
Publicado: (2022)

Repurposing FDA-approved drugs against multiple proteins of SARS-CoV-2: An in silico study
por: Akinlalu, Alfred Olaoluwa, et al.
Publicado: (2021)

PIP(3)-binding proteins promote age-dependent protein aggregation and limit survival in C. elegans
por: Ayyadevara, Srinivas, et al.
Publicado: (2016)

Phospholipidosis is a shared mechanism underlying the in vitro antiviral activity of many repurposed drugs against SARS-CoV-2
por: Tummino, Tia A., et al.
Publicado: (2021)

The study of antiviral drugs targeting SARS-CoV-2 nucleocapsid and spike proteins through large-scale compound repurposing
por: Hu, Xuqiao, et al.
Publicado: (2021)

Repurposing of antiviral drugs for COVID-19 and impact of repurposed drugs on the nervous system
por: Punekar, Madhura, et al.
Publicado: (2022)

A deep learning ensemble approach to prioritize antiviral drugs against novel coronavirus SARS-CoV-2 for COVID-19 drug repurposing
por: K., Deepthi, et al.
Publicado: (2021)

Understanding SARS‐CoV‐2 endocytosis for COVID‐19 drug repurposing
por: Glebov, Oleg O.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_uui62d3n9fituqvvr7vp6ug3tq